Thomas Friess
Roche Diagnostics GmbH
Pharma Research Penzberg
Department of Pharmacology TR-PD2
Nonnenwald 2
Germany
Name/email consistency: high
- Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression. Friess, T., Scheuer, W., Hasmann, M. Anticancer Res. (2006)
- Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Friess, T., Scheuer, W., Hasmann, M. Clin. Cancer Res. (2005)